tailieunhanh - Báo cáo y học: " The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. | Available online http content 13 3 R103 Research The international PROGRESS registry of patients with severe sepsis drotrecogin alfa activated use and patient outcomes Greg Martin1 Frank M Brunkhorst2 Jonathan M Janes3 Konrad Reinhart2 David P Sundin3 Kassandra Garnett4 and Richard Beale5 Division of Pulmonary Allergy and Critical Care Emory University 615 Michael Street Atlanta Georgia 30322 USA 2Department of Anesthesiology and Intensive Care Friedrich Schiller University Erlanger Allee 101 Jena 07743 Germany 3Lilly Research Laboratories Eli Lilly and Co. Lilly Corporate Center Indianapolis Indiana 46285 USA 4i3 StatProbe 1001 Winstead Drive Cary North Carolina 27513 USA intensive Care Unit Guy s and St Thomas Hospital Lambeth Palace Road London SE1 7EH UK Corresponding author Richard Beale Received 18 Nov 2008 Revisions requested 5 Jan 2009 Revisions received 6 Mar 2009 Accepted 30 Jun 2009 Published 30 Jun 2009 Critical Care 2009 13 R103 doi cc7936 This article is online at http content 13 3 R1 03 2009 Martin et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction Since the launch of drotrecogin alfa activated DrotAA institutions and individual countries have published data on its use in clinical practice based on audit or registry data. These studies were limited in size and geographic locale and included patients with greater disease severity and higher mortality than those in clinical trials. The purpose of this study was to compare baseline characteristics and clinical outcomes using appropriate statistical adjustments of patients treated or not treated with DrotAA from the international PROGRESS Promoting Global Research .